

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

On May 17, 2004

TOWNSEND and TOWNSEND and CREW LLP

By: Sylvia E. Arnold

Sylvia E. Arnold



PATENT
Attorney Docket No.: 016930-001022US
Client Reference No.: 3015

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Douglas Antelman et al.

Application No.: 09/315,116

Filed: May 19, 1999

For: METHODS OF TREATING
HYPERPROLIFERATIVE DISORDERS
USING RETINOBLASTOMA FUSION
PROTEINS

Group Director: 1636

Examiner: Sumesh Kaushal

Art Unit: 1636

INFORMATION DISCLOSURE
STATEMENT UNDER
37 CFR §1.97 and §1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. Copies of the references are attached to the Response filed herewith and are therefore not attached to this Information Disclosure Statement.

It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

05/24/2004 AWONDAF1 00000055 09315116

02 FC:1806 180.00 DA


This IDS is being filed on or before payment of the issue fee.

CERTIFICATION

I hereby certify that no item of information contained in the Information Disclosure Statement filed herewith was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.


Please charge the IDS fee of \$180 to Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Chris J. Ullsperger
Reg. No. 48,006

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 925-472-5000
Fax: 925-472-8895
CJU:sea



Substitute Form 1449 (Rev. 10-01-99) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	09/315,116	
			Filing Date	May 19, 1999	
			First Named Inventor	Antelman, Douglas	
			Art Unit	1636	
			Examiner Name	Sumesh Kaushal	
Sheet	3	of		Attorney Docket Number	016930-001022US

U.S. PATENT DOCUMENTS+					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number Kind Code ² (if known)			
		US-			

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶ <input type="checkbox"/>
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	0001	WILLS, et al., Development and Characterization of Recombinant Adenoviruses Encoding Human p53 for Gene Therapy of Cancer, Human Gene Therapy (September 1994), pgs. 1079-1088, volume 5, Mary Ann Liebert, Inc. Publishers	
	0002	SCHULER, et al., A Phase I Study of Adenovirus-Mediated Wild-Type p53 Gene Transfer in Patients with Advanced Non-Small Cell Lung Cancer, Human Gene Therapy (September 1998), pgs. 2075-2082, Mary Ann Liebert, Inc. Publishers	
	0003	NIELSEN, et al., Combination Therapy with the Farnesyl Protein Transferase Inhibitor SCH66336 and SCH58500 (p53 Adenovirus) in Preclinical Cancer Models, Cancer Research (December 1, 1999), pgs 5896-5901, volume 59.	
	0004	NIELSEN, et al., p53 Tumor Suppressor Gene Therapy for Cancer, Cancer Gene Therapy (1998), pgs. 52-63, Vol. 5, No. 1.	
	0005	REID, et al., Intravascular Adenoviral Agents in Cancer Patients: Lessons From Clinical Trials, Cancer Gene Therapy (2002), pgs. 980-986, Nature Publishing Group.	
	0006	WILLS, et al., Tissue-Specific Expression of an Anti-Proliferative Hybrid Transgene from the Human Smooth Muscle α -actin Promoter Suppresses Smooth Muscle Cell Proliferation and Neointima Formation, Gene Therapy (2001), pgs. 1847-1854, Nature Publishing Group.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.